Table 3.
Signal strength of reports of IXE with preferred terms (PTs) ≥ 45 from FAERS.
| PT | Case numbers | ROR(95%Cl) | PRR(χ2) | EBGM(EBGM05) | IC(IC025) |
|---|---|---|---|---|---|
| Injection site pain | 3,581 | 16.05(15.51–16.61) | 15.06 (46163.17) | 14.75 (14.33) | 3.88 (3.83) |
| Injection site erythema | 2,014 | 26.19(25.03–27.41) | 25.26 (45249.64) | 24.36 (23.45) | 4.61 (4.54) |
| Injection site swelling | 1,519 | 28.29 (26.86–29.8) | 27.53 (37306.84) | 26.46 (25.33) | 4.73 (4.65) |
| Injection site reaction | 1,459 | 30.4 (28.83–32.06) | 29.62 (38626.91) | 28.37 (27.14) | 4.83 (4.75) |
| Injection site pruritus | 695 | 14.49(13.44–15.63) | 14.32 (8434.19) | 14.03 (13.17) | 3.81 (3.7) |
| Injection site urticaria | 606 | 32.49(29.93–35.27) | 32.14 (17432.15) | 30.68 (28.64) | 4.94 (4.82) |
| Injection site mass | 549 | 15.18(13.94–16.52) | 15.03 (7034.93) | 14.72 (13.71) | 3.88 (3.75) |
| Injection site hemorrhage | 512 | 7.79 (7.13–8.5) | 7.72 (2964.55) | 7.64 (7.1) | 2.93 (2.81) |
| Nasopharyngitis | 475 | 2.81 (2.56–3.07) | 2.79 (545.06) | 2.78 (2.58) | 1.48 (1.34) |
| Injection site rash | 468 | 20.43(18.63–22.41) | 20.27 (8317.37) | 19.69 (18.22) | 4.3 (4.16) |
| Injection site warmth | 451 | 38.5 (35–42.35) | 38.19 (15,434) | 36.13 (33.36) | 5.18 (5.04) |
| Urticaria | 436 | 3.12 (2.84–3.43) | 3.1 (618.94) | 3.09 (2.86) | 1.63 (1.49) |
| Injection site bruising | 415 | 6.66 (6.05–7.34) | 6.62 (1962.04) | 6.56 (6.05) | 2.71 (2.57) |
| Sinusitis | 397 | 4.34 (3.93–4.79) | 4.31 (1005.2) | 4.29 (3.95) | 2.1 (1.96) |
| Influenza | 293 | 2.81 (2.51–3.16) | 2.81 (339.55) | 2.8 (2.54) | 1.48 (1.32) |
| Cellulitis | 261 | 6.08 (5.38–6.87) | 6.06 (1093.16) | 6.01 (5.43) | 2.59 (2.41) |
| Ear infection | 213 | 8.66 (7.56–9.91) | 8.63 (1417.93) | 8.53 (7.61) | 3.09 (2.89) |
| Upper respiratory tract infection | 185 | 4.51 (3.9–5.21) | 4.5 (500.14) | 4.47 (3.96) | 2.16 (1.95) |
| Bronchitis | 175 | 2.76 (2.38–3.21) | 2.76 (195.63) | 2.75 (2.43) | 1.46 (1.24) |
| Fungal infection | 172 | 5.84 (5.02–6.78) | 5.82 (681.08) | 5.78 (5.1) | 2.53 (2.31) |
| Herpes zoster | 135 | 2.53 (2.14–3) | 2.53 (124.68) | 2.53 (2.19) | 1.34 (1.09) |
| Oral candidiasis | 134 | 12.94 (10.9–15.35) | 12.91 (1443.68) | 12.68 (10.98) | 3.66 (3.41) |
| Candida infection | 125 | 7.24 (6.07–8.63) | 7.22 (663.12) | 7.16 (6.17) | 2.84 (2.58) |
| Pharyngitis streptococcal | 111 | 11.46 (9.49–13.82) | 11.43 (1038.89) | 11.25 (9.62) | 3.49 (3.22) |
| Inflammatory bowel disease | 98 | 20.41(16.69–24.97) | 20.38 (1751.5) | 19.79 (16.73) | 4.31 (4.01) |
| Colitis | 94 | 2.72 (2.22–3.33) | 2.72 (101.63) | 2.71 (2.29) | 1.44 (1.14) |
| Staphylococcal infection | 93 | 3.83 (3.12–4.69) | 3.82 (192.71) | 3.81 (3.21) | 1.93 (1.63) |
| Irritable bowel syndrome | 83 | 4.65 (3.74–5.77) | 4.64 (235.56) | 4.62 (3.85) | 2.21 (1.89) |
| Tooth infection | 79 | 6.62 (5.3–8.26) | 6.61 (372.37) | 6.55 (5.44) | 2.71 (2.39) |
| Respiratory tract infection | 66 | 2.74 (2.15–3.49) | 2.74 (72.59) | 2.73 (2.23) | 1.45 (1.1) |
| Diverticulitis | 64 | 2.54 (1.99–3.25) | 2.54 (59.41) | 2.53 (2.06) | 1.34 (0.98) |
| Immune system disorder | 60 | 4.84 (3.75–6.24) | 4.83 (181.03) | 4.8 (3.88) | 2.26 (1.89) |
| Kidney infection | 53 | 2.87 (2.19–3.76) | 2.87 (64.13) | 2.86 (2.28) | 1.51 (1.12) |
| Conjunctivitis | 52 | 2.95 (2.25–3.88) | 2.95 (66.69) | 2.94 (2.34) | 1.56 (1.16) |
| Tuberculosis | 52 | 4.54 (3.45–5.96) | 4.54 (142.36) | 4.51 (3.59) | 2.17 (1.78) |
| Gastroenteritis viral | 47 | 2.95 (2.22–3.93) | 2.95 (60.38) | 2.94 (2.31) | 1.56 (1.14) |
| Malignant melanoma | 46 | 3.55 (2.66–4.74) | 3.55 (83.71) | 3.53 (2.77) | 1.82 (1.4) |